Shire Acquires Baxalta in $32 Billion Deal
Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.
Shire and Baxalta have announced $32 billion agreement under which Shire will combine with Baxalta, creating a company with the top rare diseases platform in revenue and pipeline depth, the companies reported in a Jan. 11, 2016 press statement. The new company is projected to achieve annual revenues of $20 billion by 2020.
Shire reports that the combined companies will have products in growing franchises in hematology; immunology; neuroscience; lysosomal storage diseases; gastrointestinal/endocrine; hereditary angioedema; and oncology; as well as a late-stage ophthalmics pipeline.
Baxalta shareholders will hold approximately 34% ownership in the combined company. The parties expect the transaction to close mid-2016.
Source: Shire
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
